NKTRNektar Therapeutics
NKTR
Nektar Therapeutics8,790
Mkt Cap
$2.07BVolume
837,535.0052W High
$77.0052W Low
$6.48PE Ratio
-7.06NKTR Fundamentals
Price
$72.22Prev Close
$74.84Open
$74.9050D MA
$56.05Beta
1.85Avg. Volume
1.76MEPS (Annual)
-$9.73P/B
16.38Rev/Employee
$876,698.41$616.46
Hudson Bay Capital Management LP Purchases Shares of 107,678 Nektar Therapeutics $NKTR
Hudson Bay Capital Management LP acquired a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 107,678 shares of the biopharmaceutical company's stock, valued at approximately...
MarketBeat·2d ago
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Nektar Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2d ago
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire NEW YORK, March 21, 2026 NEW YORK, March 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law...
PR Newswire·2d ago
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...
Business Wire·2d ago
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting Data from Phase 2b Studies for Rezpegaldesleukin...
PR Newswire·2d ago
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to...
PR Newswire·3d ago
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with...
PR Newswire·3d ago
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar...
PR Newswire·3d ago
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: SueWallSt
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: SueWallSt NKTR...
PR Newswire·3d ago
HC Wainwright Issues Positive Estimate for NKTR Earnings
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for Nektar Therapeutics in a research report issued on Tuesday, March 17th. HC Wainwright analyst A. He now anticipates that the biopharmaceutical company will post ear...
MarketBeat·4d ago
<
1
2
...
>